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In contrast to conventional chemotherapeutic agents, modern anticancer therapies are aimed at attacking 
specific targets in a tumor. While these therapies show promising clinical effects, their success is limited by 
the development of resistance to the antitumor agent, a phenomenon that is well known in regular cancer 
therapies. As illustrated in a novel study by Debies and colleagues in The Journal of Clinical Investigation, 
mouse models for cancer serve as promising tools for advancing our understanding of the tumor response 
to targeted therapy. However, the experimental setup and selected model system may evoke unexpected 
escape mechanisms. Here, we discuss the promises and pitfalls of these approaches.Conceptually, “targeted therapies” against 
aberrantly expressed or mutated cellular 
components that are crucial for tumor 
growth and survival seem promising. 
They are likely less toxic for normal cells 
in which these components are unal-
tered and present at physiological levels. 
Among the targeted anticancer therapies 
that have successfully been introduced 
in the clinic are trastuzumab (Herceptin) 
and imatinib (Gleevec), which are admin-
istered as adjuvant therapy to patients 
with HER2/NEU-positive breast cancer 
and as first-line therapy for patients with 
chronic myeloid leukemia (CML), respec-
tively. While these treatments present 
Figure 1. Mouse Models for Tumor Relapse
(A) Debies et al. studied tumor relapse in a mouse 
model for breast cancer. Mammary tumors are in-
duced upon doxycyclin (DOX)-mediated activation 
of a tetO-Wnt1 transgene. DOX withdrawal shuts 
off Wnt1 transgene expression, causing tumors to 
regress. Potent escape mechanisms in the form 
of DOX-independent Wnt1 transgene reactivation, 
oncogenic mutations in β-catenin, or compensa-
tory bypass allow tumor relapse.
(B) This model mimics targeted therapy with novel 
anticancer agents such as the small-molecule 
BCR/ABL inhibitor imatinib. In BCR/ABL-driven 
CML tumor, relapse frequently occurs when cells 
acquire a T315I point mutation in BCR/ABL, ren-
dering it insensitive to imatinib. Similarly, in lung 
cancer driven by EGFR hyperactivation, the ac-
quirement of a T790M point mutation in EGFR 
desensitizes tumor cells to the EGFR inhibitors 
erlotinib or gefitinib. In addition, compensatory 
bypass mechanisms, such as methylation of the 
SOCS1 gene promoter in BCR/ABL-driven CML, 
can also promote resistance to targeted therapies 
(Saudemont et al., 2007).a major advancement and often result 
in long-term patient survival, resistance 
frequently develops.
These targeted therapies are par-
ticularly appealing if they exploit a phe-
nomenon known as “oncogene addic-
tion,” which refers to the fact that even 
advanced tumors remain dependent on 
initiating oncogenic lesions. While this 
was first demonstrated to be the case 
for MYC in hematological malignancies 
(Jain et al., 2002), it holds true for many 
tumors. Although inhibition of the initi-
ating oncogenic activity often causes 
tumor regression, tumors frequently 
relapse. This can occur by “target reacti-Cancer vation,” i.e., by acquiring novel mutations 
in the drug target rendering it refractory 
to treatment, as observed for the ima-
tinib target BCR/ABL (Gorre et al., 2001) 
and the gefitinib/erlotinib target EGFR in 
lung cancer patients (Pao et al., 2005). 
Alternatively, tumors can activate com-
pensatory signaling pathways, allowing 
them to bypass the effects of drug treat-
ment (Stommel et al., 2007).
Current mouse models for cancer, 
carrying inducible oncogenic lesions, 
allow sporadic tumor formation. Result-
ing tumors, which often closely mimic 
human disease, offer the opportunity 
for preclinical testing and dissecting Cell 13, January 2008 ©2008 Elsevier Inc. 
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ing tumor escape. A recent study by 
Debies and colleagues made use of 
conditional Wnt1-transgenic mice (tetO-
Wnt1) to explore tumor relapse (Figure 1) 
(Debies et al., 2007). Transgene expres-
sion in these mice can be switched on 
by doxycyclin administration, causing 
tetO-Wnt1 mice to develop mammary 
tumors. Tumors regress upon doxycyclin 
withdrawal, illustrating their addiction to 
Wnt1 expression.
During a 1 year follow-up, 10 of 34 
regressed tumors relapsed. Sixty per-
cent of the relapses resulted from target 
reactivation, as measured by the expres-
sion of Wnt/β-catenin target genes. In 
half of these, Wnt1 transgene expression 
was reactivated in a doxycyclin-inde-
pendent manner. More strikingly, the 
other half expressed oncogenic forms of 
the downstream Wnt-signaling compo-
nent β-catenin, underscoring the strong 
dependence of these tumors on the 
Wnt/β-catenin pathway. The remaining 
40% of relapsed tumors did not express 
Wnt/β-catenin target genes, suggesting 
that compensatory bypass was respon-
sible for tumor escape.
When the authors next studied tumor 
relapse of tetO-Wnt1-induced tumors in 
a p53+/− background, they observed a 
reduced incidence of Wnt/β-catenin tar-
get gene activation. Not only did fewer 
tumors display Wnt1 transgene reactiva-
tion, none of these relapsed tumors car-
ried oncogenic mutations in β-catenin. 
In contrast, 75% of the tumors that did 
display target reactivation had under-
gone p53 LOH. The authors hypothesize 
that re-expression of Wnt-pathway tar-
get genes in these tumors results from 
loss of a p53-mediated signal antagoniz-
ing Wnt/β-catenin signaling.
To find out whether this effect might 
also be mediated by loss of other p53-
pathway components (such as p19Arf) 
or other tumor suppressor pathways 
(such as the p16/Rb pathway) Debies 
et al. crossed their tetO-Wnt1 mice 
onto p16Ink4a/p19Arf-, p16Ink4a-, or 
p19Arf-deficient backgrounds. Tumor 
regression was similarly impaired on a 
p19Arf- or p53-deficient background, 
while p16Ink4a loss did not affect either 
regression or relapse. In addition, 
p19Arf deficiency resembled Ink4a/Arf 
deficiency in promoting tumor escape.  Cancer Cell 13, January 2008 ©2008 ElsevAlthough the nature of the compensa-
tory bypass mechanisms in each of the 
genetic backgrounds remains unknown, 
this study does suggest that depending 
on the genetic make-up of the primary 
lesion, tumors may be more prone to 
relapse by either target reactivation or 
compensatory bypass. Moreover, the 
presence of oncogenic mutations in 
β-catenin in the wild-type background 
underscores that unexpected and pow-
erful escape mechanisms may occur, 
which likely differ with tumor type and 
experimental setup.
In spite of the valuable information 
that can be obtained from mouse model 
studies as described above, the system 
does have its drawbacks. First, while 
the switching of conditional oncogenes 
allows direct control over the initiat-
ing oncogenic lesion, it is by no means 
identical to administering an anticancer 
drug. It therefore remains to be seen 
whether true therapeutic agents (such 
as small-molecule Wnt-pathway inhibi-
tors) would illicit the same responses. 
Recent work by Rottenberg and col-
leagues has shown the power and fea-
sibility of such studies by testing a num-
ber of conventional chemotherapeutic 
agents in a mouse mammary tumor 
model (Rottenberg et al., 2007).
Second, although Wnt-pathway hyper-
activation is a powerful means of induc-
ing mammary tumors in mice, lesions 
in the Wnt/β-catenin pathway are only 
rarely observed in human breast cancers, 
leaving the value of this mouse model for 
human breast cancer questionable.
Third, while the possibility to sample 
the role of distinct oncogenic lesions in 
tumor relapse is attractive, the use of 
mice carrying germline lesions is rather 
artificial. In mice, the engineered lesion 
in the presumed compensatory path-
way is present from the outset in both 
stromal and tumor cells. This may affect 
tumor initiation and growth, and as such, 
it could skew tumor behavior during 
regression and relapse. For instance, 
p19Arf loss not only influences the 
response of CML to imatinib, but also 
enhances tumor oncogenicity, raising 
the question whether tumors in a p19Arf-
proficient and -deficient background are 
similar or not (Williams et al., 2006). Like-
wise, in a p53+/− background, the system 
is greatly predisposed to p53 LOH. In ier Inc.contrast, in humans, the lesions in com-
pensatory pathways will occur only spo-
radically and provide a growth or survival 
advantage to rare tumor cells under the 
selective pressure of targeted therapy. 
In real clinical practice, other modes 
of resistance may be more important. 
Future studies should, therefore, attempt 
to mimic human disease more closely. 
This could, for instance, be achieved by 
including an inducible RNAi knockdown 
construct in the mouse model of choice, 
such that a given compensatory path-
way can be (in)activated in tumor cells 
concomitant with annihilation of the initi-
ating oncogenic lesion.
In this regard, recent studies on mouse 
models for CML are exemplary. This 
tumor model has been well characterized, 
and tumors are readily induced following 
infection of bone marrow stem cells with 
a BCR/ABL-expressing retrovirus. More-
over, BCR/ABL-driven leukemia in mice 
is susceptible to treatment with imatinib. 
This has allowed researchers to elucidate 
resistance mechanisms, as illustrated 
by a recent study which revealed that 
cytokines in the tumor microenvironment 
were able to mediate CML resistance to 
imatinib in a p19Arf-deficient background 
(Williams et al., 2007).
Can we point to a common denomina-
tor facilitating tumor relapse? Interest-
ingly, a number of studies have shown an 
important role for antiapoptotic pathways 
acting through p53, Bcl2, and Akt in pro-
moting tumor escape in a range of differ-
ent settings (Berns et al., 2007; Martins et 
al., 2006; Ventura et al., 2007). These sur-
vival pathways may mediate resistance to 
a wide variety of targeted therapies.
A future challenge is to identify the 
genes that can evoke tumor relapse. As 
indicated above, these will likely differ 
with tumor type, targeted therapy, and 
genetic make up of the primary lesion. 
While genome-wide approaches such as 
transcriptome and proteome profiling will 
be a major help in pinning down these 
events (Stommel et al., 2007), experi-
mental approaches that combine mouse 
models for tumor escape with gene-
hunting techniques may also pay off. A 
nice example of the latter was recently 
reported by Miething and colleagues, 
who combined imatinib treatment in a 
BCR/ABL-driven mouse model for CML 
with retroviral insertional mutagenesis 
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identification of Runx3 as a proviral target 
that facilitated tumor relapse upon tar-
geted therapy with imatinib. These new 
mouse models and genomic techniques 
can provide us with unique reagents to 
uncover new resistance mechanisms, 
thereby allowing us to design strategies 
to overcome resistance that can subse-
quently be tested in cancer patients.
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